Proteomics

Dataset Information

0

Exposure of Mycobacterium tuberculosis to thioridazine alters the cell envelope permeability; an alternative mechanism for the synergistic effects with other antibiotics


ABSTRACT: The emergence of multidrug resistant tuberculosis and the increasing level of resistance urges the search for alternative drugs in treatment. Several neuroleptics, like thioridazine, reveal activity against Mycobacterium tuberculosis. Thioridazine was even successfully applied in compassionate therapy of extensively drug resistant tuberculosis in patients when added to other second and third line antibiotics. The synergistic effects between thioridazine and other anti-tuberculosis drugs is usually assigned to the inhibition of efflux pumps by thioridazine. Using an unbiased proteomic approach, we set out to unravel the molecular mechanism of this potential new anti-tuberculosis component by examining the impact of continuous thioridazine exposure on the proteome of M. tuberculosis. We discovered that under the influence of thioridazine several proteins involved in the maintenance of the cell wall permeability barrier are differentially regulated, while none of the known mycobacterial efflux pumps was differentially regulated on the protein level. By assessing accumulation of fluorescent dyes in M. tuberculosis over time, we demonstrated that long-term drug exposure of M. tuberculosis indeed affected the mycobacterial cell envelope and increased the permeability towards both hydrophilic and hydrophobic compounds. Furthermore, we demonstrated that treatment of M. tuberculosis with thioridazine altered the composition of the plasma membrane. Thioridazine induced an increase in cell envelope permeability, and thereby the enhanced uptake of compounds, this could explain the previously reported synergistic effects between thioridazine and other anti-tuberculosis drugs. Although the hypothesis of higher intercellular drug concentrations by THZ has not changed in this study, the more exact knowledge on its mode of action is a major step forward. This new insight in the molecular mechanism of this anti-tuberculosis compound could facilitate further development of this class of drugs for application in drug therapy of multidrug resistant tuberculosis. In fact, the efficacy of many existing drugs could be improved significantly.

INSTRUMENT(S): LTQ FT

ORGANISM(S): Mycobacterium Tuberculosis H37rv

DISEASE(S): Tuberculosis

SUBMITTER: Jeroen de Keijzer  

LAB HEAD: Peter van Veelen

PROVIDER: PXD001208 | Pride | 2016-07-06

REPOSITORIES: Pride

altmetric image

Publications

Thioridazine Alters the Cell-Envelope Permeability of Mycobacterium tuberculosis.

de Keijzer Jeroen J   Mulder Arnout A   de Haas Petra E W PE   de Ru Arnoud H AH   Heerkens Evy M EM   Amaral Leonard L   van Soolingen Dick D   van Veelen Peter A PA  

Journal of proteome research 20160509 6


The increasing occurrence of multidrug resistant tuberculosis exerts a major burden on treatment of this infectious disease. Thioridazine, previously used as a neuroleptic, is active against extensively drug resistant tuberculosis when added to other second- and third-line antibiotics. By quantitatively studying the proteome of thioridazine-treated Mycobacterium tuberculosis, we discovered the differential abundance of several proteins that are involved in the maintenance of the cell-envelope pe  ...[more]

Similar Datasets

2020-08-15 | E-MTAB-6191 | biostudies-arrayexpress
2008-03-11 | GSE10757 | GEO
2013-04-24 | E-BUGS-134 | biostudies-arrayexpress
2018-12-26 | GSE115495 | GEO
2018-09-16 | GSE120009 | GEO
2020-10-06 | GSE148341 | GEO
2022-01-19 | GSE189424 | GEO
2018-09-18 | GSE120082 | GEO
2024-03-01 | E-MTAB-13761 | biostudies-arrayexpress
| PRJNA107537 | ENA